<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GRIN2A Gene</th>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">GRIN1</td>
<td>Subunit heterotetramerization</td>
</tr>
<tr>
<td class="label">DLG4 (PSD-95)</td>
<td>PDZ domain binding</td>
</tr>
<tr>
<td class="label">CaMKII</td>
<td>Kinase substrate</td>
</tr>
<tr>
<td class="label">SRC</td>
<td>Tyrosine phosphorylation</td>
</tr>
<tr>
<td class="label">DARP32</td>
<td>Scaffold binding</td>
</tr>
<tr>
<td class="label">Homer</td>
<td>Proline-rich motif binding</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">10 edges</a></td>
</tr>
</table>
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GRIN2A Gene</th>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">GRIN1</td>
<td>Subunit heterotetramerization</td>
</tr>
<tr>
<td class="label">DLG4 (PSD-95)</td>
<td>PDZ domain binding</td>
</tr>
<tr>
<td class="label">CaMKII</td>
<td>Kinase substrate</td>
</tr>
<tr>
<td class="label">SRC</td>
<td>Tyrosine phosphorylation</td>
</tr>
<tr>
<td class="label">DARP32</td>
<td>Scaffold binding</td>
</tr>
<tr>
<td class="label">Homer</td>
<td>Proline-rich motif binding</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">10 edges</a></td>
</tr>
</table>
The GRIN2A gene encodes the GluN2A protein (also known as NR2A or NMDAR2A), a critical subunit of the N-methyl-D-aspartate (NMDA) receptor, a subtype of ionotropic glutamate receptors that plays a fundamental role in synaptic plasticity, learning, memory, and excitatory neurotransmission in the central nervous system[@cullcandy2003]. The NMDA receptor is a heterotetrameric ion channel typically composed of two GluN1 (encoded by GRIN1) subunits and two variable subunits (GluN2A, GluN2B, GluN2C, or GluN2D) or occasionally GluN3 subunits[@paoletti2013]. GRIN2A is one of the most extensively studied glutamate receptor genes due to its pivotal role in synaptic function and its involvement in numerous neurological and psychiatric disorders.
The GRIN2A gene is located on chromosome 16p13.2 and spans approximately 190 kilobases. It consists of 33 coding exons that encode a protein of 1,838 amino acids. The gene is expressed predominantly in the forebrain, with high levels in the hippocampus and cerebral cortex—brain regions critical for cognitive function[@akazawa1994]. Expression patterns change during development: GluN2A is expressed at low levels in early postnatal life but increases dramatically during a developmental "switch" around the third week in rodents (corresponding to adolescence in humans), where the subunit composition of NMDA receptors shifts from predominantly GluN2B-containing to GluN2A-containing receptors[@yashiro2008].
The GluN2A subunit is a large transmembrane protein with an extracellular N-terminal domain (NTD), a ligand-binding domain (LBD), a transmembrane domain (TMD) forming the ion channel pore, and an intracellular C-terminal domain (CTD)[@karakas2014]. The extracellular domains interact with the GluN1 subunit and with glutamate (the agonist) and glycine (the co-agonist). The C-terminal domain is particularly important for intracellular signaling, as it contains multiple phosphorylation sites and binding sites for postsynaptic density proteins including PSD-95, CaMKII, and Shank[@sheng2000].
The subunit composition of the NMDA receptor dramatically influences its functional properties. GluN2A-containing receptors have faster deactivation kinetics compared to GluN2B-containing receptors, influence long-term potentiation (LTP) more efficiently, and show reduced calcium permeability[@erreger2005]. This developmental shift from GluN2B-dominant to GluN2A-dominant receptors is thought to represent a maturation of synaptic circuitry that fine-tunes synaptic plasticity during critical periods of brain development.
GRIN2A expression is subject to complex transcriptional regulation. The gene promoter contains multiple transcription factor binding sites, including sites for REST (RE1-silencing transcription factor), SP1, USF1/2, and neuronal activity-dependent factors like CREB (cAMP response element-binding protein)[@klein2006]. Epigenetic regulation, including DNA methylation and histone modifications, also plays a role in GRIN2A expression, with activity-dependent demethylation observed in the promoter region following neuronal activation[@huang2002].
NMDA receptors serve as coincidence detectors in synaptic plasticity. Their unique biophysical properties—their reliance on both glutamate binding and membrane depolarization for channel opening—enable them to detect the temporal coincidence of presynaptic release and postsynaptic depolarization, the core requirement for Hebbian plasticity[@bliss1993]. When both conditions are met, the channel opens to allow calcium influx, which serves as the critical second messenger triggering downstream signaling cascades that underlie long-term potentiation (LTP) and long-term depression (LTD)[@malenka2004].
GluN2A-containing NMDA receptors are particularly important for LTP induction. The subunit composition influences the threshold for LTP: receptors containing GluN2A show a higher LTP induction threshold compared to GluN2B-containing receptors, likely due to their faster kinetics and reduced calcium influx per synaptic event[@berberich2005]. This may explain why the developmental increase in GluN2A expression correlates with reduced plasticity in mature neurons.
The GluN2A C-terminal domain interacts with numerous postsynaptic density (PSD) proteins, forming a large signaling complex often called the postsynaptic density (PSD) scaffold[@kim2004]. Key interactors include:
Multiple lines of evidence implicate GRIN2A dysregulation in Alzheimer's disease (AD). Postmortem studies have shown reduced GRIN2A mRNA and protein expression in the hippocampus and prefrontal cortex of AD patients[@hyman1988]. This reduction may contribute to synaptic dysfunction and cognitive decline by impairing NMDA receptor-dependent plasticity mechanisms. Additionally, amyloid-beta (Aβ) oligomers, the putative neurotoxic species in AD, directly impair NMDA receptor function and reduce GRIN2A expression through mechanisms involving oxidative stress and inflammatory signaling[@shankar2008].
The amyloid cascade hypothesis has been extended to include NMDA receptor dysfunction as a downstream effect of Aβ accumulation. Aβ oligomers bind to NMDA receptors and cause their internalization, reducing synaptic NMDA receptor density and impairing LTP[@li2011]. This effect appears to be subunit-specific, with GluN2A-containing receptors being more vulnerable to Aβ-induced internalization in some studies.
Therapeutic targeting of NMDA receptors in AD has been explored. Memantine, an FDA-approved NMDA receptor antagonist for moderate-to-severe AD, acts as a low-affinity, voltage-dependent blocker that preferentially targets extrasynaptic NMDA receptors while sparing synaptic receptors, theoretically preserving physiological plasticity while reducing excitotoxicity[@parsons2007]. However, the clinical benefits of memantine are modest, highlighting the complexity of NMDA receptor dysfunction in AD.
GRIN2A is also implicated in Parkinson's disease (PD) and related disorders. Postmortem studies have reported altered GRIN2A expression in the substantia nigra and striatum of PD patients[@hunt1991]. The dopaminergic system modulates NMDA receptor function through direct phosphorylation of GluN2A subunits by dopamine-regulated Src family kinases[@oh1999]. Loss of dopaminergic input in PD may therefore disrupt NMDA receptor signaling in the basal ganglia, contributing to motor symptoms.
Additionally, leucine-rich repeat kinase 2 (LRRK2), the most common genetic cause of familial PD, directly interacts with NMDA receptor subunits. LRRK2 phosphorylates GluN2A at specific sites, enhancing receptor function and potentially contributing to excitotoxicity in PD[@jantaratnotai2010]. Studies in LRRK2 transgenic mice show altered NMDA receptor subunit composition and enhanced vulnerability to excitotoxic insults.
GRIN2A dysfunction has been implicated in several other neurological conditions:
GRIN2A is one of the most commonly mutated genes in the epilepsy-aphasia spectrum (EAS) and Landau-Kleffner syndrome (LKS)[@lesca2015]. These disorders, characterized by language regression and epilepsy, are associated with heterozygous de novo mutations in GRIN2A that cause loss-of-function of the NMDA receptor. Over 150 pathogenic variants have been identified, including nonsense, frameshift, splice site, and missense mutations[@strehlow2019].
Interestingly, some GRIN2A missense mutations cause gain-of-function effects, leading to excessive NMDA receptor activity and causing a distinct clinical phenotype including epilepsy, developmental delay, and often ictal dysgraphia—inability to write during seizures[@carvill2013]. These gain-of-function mutations cause increased channel open time or reduced magnesium block, leading to neuronal hyper-excitability.
Beyond rare pathogenic variants, common single nucleotide polymorphisms (SNPs) in GRIN2A have been associated with:
Given the central role of GRIN2A-containing NMDA receptors in neurological function, several therapeutic strategies have been developed:
Advances in gene therapy offer new possibilities for targeting GRIN2A. CRISPR-Cas9 systems can be used to:
GRIN2A engages multiple downstream signaling pathways:
Studying GRIN2A function employs multiple model systems:
Key methods for studying GRIN2A include:
The GRIN2A gene encodes a critical subunit of the NMDA receptor that governs synaptic plasticity, learning, and memory. Its dysregulation contributes to multiple neurodegenerative and neuropsychiatric disorders, making it an important therapeutic target. Understanding the complex regulation of GRIN2A expression and function, along with the development of subunit-selective modulators and gene therapies, offers hope for treating conditions ranging from Alzheimer's disease to epilepsy. As research continues to elucidate the precise molecular mechanisms by which GRIN2A influences neural function, new therapeutic opportunities will undoubtedly emerge.
The following diagram shows the key molecular relationships involving GRIN2A Gene discovered through SciDEX knowledge graph analysis: